The University of Auckland was formally opened on 23 May as Auckland University College, part of the University of New Zealand.
Prof APW Thomas received his first professional commission from industry – the Bay of Islands Coal Mining Company
Chemist James Scott Maclaurin was awarded a doctorate (DSc) for stablishing that oxygen was necessary for the dissolution of gold, an internationally significant discovery that formed the basis for much subsequent work on the cyanide process for gold extraction.
Auckland School of Mining opened.
Kathleen Curtis graduated from the University with an MA in botany. She described diseases that were directly threatening the horticulture industry and evaluated sprays and fertilisers for their control.
Heather Nicholson (née Halcrow) studied geology at Auckland University College. She produced a geological map of Waiheke Island, near Auckland, for her MSc thesis in 1953. This involved many weeks of field work. No jobs were available for women in geology in those days, so she worked as a science teacher. On retirement she returned to Auckland University and completed a PhD on New Zealand greywackes in 2003 – exactly 50 years after completing her masters degree.
Philippa Black studied geology at the University of Auckland. She has published pioneering papers on the geology of Northland and New Caledonia, and has worked in the fields of mineralogy, coal petrology and rock properties.
Developed by the Auckland Cancer Society Research Centre, the anti-cancer drug Asulacrine, was launched by Pfizer.
UniServices established as the University’s commercialisation and technology transfer company.
Canertinib, a novel EGFR Inhibitor for the treatment of various cancers was launched by Pfizer.
Spark, the University Innovation and Entrepreneurship programme launched.
Spinout company Proacta raised more than NZ$52 million to develop unique anti-cancer technology.
PowerbyProxi a spin-out company was formed to develop wireless power technology for consumer electronic devices.
‘Growing up in New Zealand’, our country’s most comprehensive longitudinal study, funded by a wide range of government agencies began.
Anti cancer drug DMXAA entered PhaseIII clinical trials across 1,000 patients worldwide, and licensed to Novartis for $890 million.
A new AUD$30 million Trans Tasman Commercialisation Fund (TTCF) set up to support innovation.
Anti cancer drug DMXAA entered Phase III clinical trials across 1,000 patients worldwide, and licensed to Novartis for $890 million.
A spin-out company HaloIPT was formed to develop Wireless Power Transfer for Electric Vehicles.
HaloIPT won the Clean Equity Monaco award for ‘Excellence in the Field of Environmental Technology Research’.
The Centre for Microbial Innovation, the Centre for Applied Economic Research, Wind Measurement Technologies, and Kumanu an industry partnering programme for technology to improve care for seniors, were launched.
IPT, the technology which allows electric cars to be charged wirelessly, hit the streets of London as part of an electric car trial.
SPARX, a computer programme for adolescent depression, won an international digital award from UNESCO’s Netexplo in Paris.
UniServices and the University of Auckland partnered with an American drug development company to launch SapVax, a biotech start up which develops novel cancer vaccines.